Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1996 1
1997 2
2003 1
2004 2
2005 6
2006 5
2008 1
2009 2
2011 1
2012 3
2013 3
2016 1
2017 1
2018 1
2021 1
2022 3
2023 4
2024 4
2025 7
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Among authors: papanastasiou p. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.
An overview of CV-MDI-QKD.
Fletcher AI, Harney C, Ghalaii M, Papanastasiou P, Mountogiannakis A, Spedalieri G, Hajomer AAE, Gehring T, Pirandola S. Fletcher AI, et al. Among authors: papanastasiou p. Rep Prog Phys. 2025 Aug 6;88(8). doi: 10.1088/1361-6633/adf4f4. Rep Prog Phys. 2025. PMID: 40720976 Review.
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.
Kingo K, Papanastasiou P, Beissert S, Lazareva S, Villa AV, Bartonova J, Ballona R, Bansal A, Martin R, Fan H, O'Doherty C, Ravichandran S, Magnolo N. Kingo K, et al. Among authors: papanastasiou p. Paediatr Drugs. 2025 Nov;27(6):749-759. doi: 10.1007/s40272-025-00715-4. Epub 2025 Aug 28. Paediatr Drugs. 2025. PMID: 40874954 Free PMC article. Clinical Trial.
Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.
Krasowska D, Gambichler T, Cortés C, Horev A, Compagno N, Dahale SS, Papanastasiou P, Keefe D. Krasowska D, et al. Among authors: papanastasiou p. J Eur Acad Dermatol Venereol. 2023 Mar 27. doi: 10.1111/jdv.19063. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 36971771
47 results